Advantum Health, a leader in technology-enabled revenue cycle management solutions, announced that Clarissa Jones has joined the organization as Corporate Director of Brand & Communications. In this role, Jones leads Advantum's brand and communications strategy, overseeing storytelling, marketing, and digital engagement initiatives that strengthen the company's presence in the healthcare industry. She works closely with […]

Large Korean cohort study reveals a link between restless legs syndrome and Parkinson's disease, highlighting opportunities for early detection and potential prevention Researchers from Korea University Ansan Hospital and collaborators report that patients with restless legs syndrome (RLS) face a higher risk of developing Parkinson's disease (PD). In a nationwide cohort of nearly 20,000 people,

MetaVia Inc. (Nasdaq: MTVA) (“MetaVia” or the “Company”), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par value $0.001 (“common stock”), effective at 5:00 p.m. Eastern Time on December 4, 2025. Beginning on December 5, 2025, the common stock will trade on The

The SOLiD ALLIANCE nBIU Headend delivers double the capacity in 70 percent less space for high-performance in-building connectivity – SOLiD, the cellular in-building coverage leader, introduced the latest addition to the SOLiD ALLIANCE 5G distributed antenna system (DAS) platform for multi-operator cellular networks. The new BTS Interface Unit (nBIU) is the fourth-generation headend for the

Delivering Essential Data Center Capacity in Supply-ConstrainedDowntown Atlanta Market RadiusDC, a leading provider of highly connected, innovative and resilient data center solutions, has announced the acquisition of the mission-critical carrier-hotel facility located at 55 Marietta Street NW in Downtown Atlanta. https://mma.prnewswire.com/media/2480705/RadiusDC_Logo.jpg The 403,000 square-foot, 21-story carrier hotel is strategically positioned at the hub of connectivity

— Intensifying AI demands continue to proliferate across aerospace and defense, automotive, consumer electronics, data center, industrial automation andMedTech — Advances continue in thermal management, power efficiency, optical connectivity, electrification, personalization along with modular architecture and open standards — Continued collaboration needed to ensure supply optionality, localized manufacturing and pragmatic, AI-driven data intelligence to drive

(NASDAQ:GURE), SHOUGUANG, China, Dec. 02, 2025 (GLOBE NEWSWIRE) — Gulf Resources, Inc. (“Gulf Resources,” “we,” or the “Company”) announced today that it received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's requirement under Listing Rule 5550(a)(2). The hearing before the Hearings Panel

(NASDAQ:BFRI),(NASDAQ:BFRIW), sNDA for treatment of sBCC with Ameluz(R)-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025 First Phase 3 PDT study in patients with sBCC in the United States submitted to FDA Primary and key secondary endpoints met with high statistical significance (p <0.0001) Favorable recurrence outcomes at one-year follow-up BCC

(CNSX:BLO.CN),(Pinksheets:BLOZF),(PinkSheets:BLOZF),(CNSX:BLO),(Boerse Frankfurt – Freiverkehr:8CT), VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to announce that it has entered into a second sales agreement for its BreathLogix unmanned alcohol screening technology with an

(NASDAQ:PALI), Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic